Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.
Hematology Am Soc Hematol Educ Program
; 2020(1): 487-493, 2020 12 04.
Article
en En
| MEDLINE
| ID: mdl-33275669
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of immunotherapy for B-cell malignancies, including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed/refractory B-cell lymphomas, outcomes in these patients remain inferior to those of patients with B-cell leukemia, regardless of therapy. Recent clinical studies and preclinical reports suggest that certain characteristics, such as the suppressive lymphoma tumor microenvironment and inferior endogenous T-cell fitness, may contribute to discrepant responses in these patients. In addition, these studies revealed that limited CAR T-cell persistence and tumor antigen escape, which also impact B-cell acute lymphoblastic leukemia, may play a more prominent role in lymphoma. Multiple promising strategies to overcome these barriers have advanced to clinical trials. In this review, we assess CAR T-cell therapies for pediatric relapsed/refractory mature B-cell lymphomas, potential obstacles diminishing antitumor activity and limiting CAR T-cell persistence, and current strategies to overcome these obstacles.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Leucemia Linfocítica Crónica de Células B
/
Leucemia-Linfoma Linfoblástico de Células Precursoras B
/
Inmunoterapia Adoptiva
/
Linfoma de Burkitt
/
Microambiente Tumoral
/
Receptores Quiméricos de Antígenos
Idioma:
En
Revista:
Hematology Am Soc Hematol Educ Program
Asunto de la revista:
HEMATOLOGIA
Año:
2020
Tipo del documento:
Article